Cargando…
Prediction of Sentinel Lymph Node Biopsy Status in Breast Cancers with PET/CT Negative Axilla
Background and Aim Prior knowledge of axillary node status can spare a lot of patients with early breast cancer morbidity due to an unnecessary axillary dissection. Our study compared various metabolic and pathological features that can predict the sentinel lymph node biopsy (SLNB) status in patien...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9296246/ https://www.ncbi.nlm.nih.gov/pubmed/35865159 http://dx.doi.org/10.1055/s-0042-1750333 |
_version_ | 1784750230431858688 |
---|---|
author | Chinnappan, Sheela Chandra, Piyush Kumar, Senthil Sridev, M.B. Jain, Deepti Chandran, Ganesan Nath, Satish |
author_facet | Chinnappan, Sheela Chandra, Piyush Kumar, Senthil Sridev, M.B. Jain, Deepti Chandran, Ganesan Nath, Satish |
author_sort | Chinnappan, Sheela |
collection | PubMed |
description | Background and Aim Prior knowledge of axillary node status can spare a lot of patients with early breast cancer morbidity due to an unnecessary axillary dissection. Our study compared various metabolic and pathological features that can predict the sentinel lymph node biopsy (SLNB) status in patients with positron emission tomography/computed tomography (PET/CT) negative axilla. Patients and Methods All consecutive patients with early breast cancers (< 5 cm) with PET/CT negative axilla who underwent breast surgery and SLNB from November 2016 to February 2020 were included. Various primary tumor (PT) pathological variables and metabolic variables on PET/CT such as maximum standardized uptake value (PT-SUV (max) ), metabolic tumor volume (PT-MTV), and total lesion glycolysis (PT-TLG) were compared using univariate and multivariate analyses for prediction of SLNB status. Results Overall 70 patients, all female, with mean age 55.6 years (range: 33–77) and mean tumor size 2.2 cm (range: 0.7–4.5), were included. SLNB was positive in 20% of patients ( n = 14) with nonsentinel nodes positive in 4% ( n = 3) patients. Comparing SLNB positive and negative groups, univariate analysis showed significant association of SLNB with low tumor grade, positive lymphovascular invasion (LVI), positive estrogen receptor (ER) status with lower mean K (i) -67 index (34.41 vs. 52.02%; p = 0.02), PT-SUV (max) (5.40 vs. 8.68; p = 0.036), PT-MTV (4.71 cc vs. 7.46 cc; p = 0.05), and PT-TLG (15.12 g/mL.cc vs. 37.10 g/mL.cc; p = 0.006). On multivariate analysis, only LVI status was a significant independent predictor of SLNB status (odds ratio = 6.23; 95% confidence interval: 1.15–33.6; p = 0.033). Conclusion SLNB is positive in approximately 20% of early breast cancers with PET/CT negative axilla and SLNB status appears to be independent of PT size. SLNB+ PTs were more likely to be LVI+ and ER + ve, with lower grade/K (i) -67/metabolic activity (SUV (max) /MTV/TLG) compared with SLNB–ve tumors. Logistic regression analysis revealed LVI status as the only significant independent predictor of sentinel lymph node status. |
format | Online Article Text |
id | pubmed-9296246 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Thieme Medical and Scientific Publishers Pvt. Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92962462022-07-20 Prediction of Sentinel Lymph Node Biopsy Status in Breast Cancers with PET/CT Negative Axilla Chinnappan, Sheela Chandra, Piyush Kumar, Senthil Sridev, M.B. Jain, Deepti Chandran, Ganesan Nath, Satish World J Nucl Med Background and Aim Prior knowledge of axillary node status can spare a lot of patients with early breast cancer morbidity due to an unnecessary axillary dissection. Our study compared various metabolic and pathological features that can predict the sentinel lymph node biopsy (SLNB) status in patients with positron emission tomography/computed tomography (PET/CT) negative axilla. Patients and Methods All consecutive patients with early breast cancers (< 5 cm) with PET/CT negative axilla who underwent breast surgery and SLNB from November 2016 to February 2020 were included. Various primary tumor (PT) pathological variables and metabolic variables on PET/CT such as maximum standardized uptake value (PT-SUV (max) ), metabolic tumor volume (PT-MTV), and total lesion glycolysis (PT-TLG) were compared using univariate and multivariate analyses for prediction of SLNB status. Results Overall 70 patients, all female, with mean age 55.6 years (range: 33–77) and mean tumor size 2.2 cm (range: 0.7–4.5), were included. SLNB was positive in 20% of patients ( n = 14) with nonsentinel nodes positive in 4% ( n = 3) patients. Comparing SLNB positive and negative groups, univariate analysis showed significant association of SLNB with low tumor grade, positive lymphovascular invasion (LVI), positive estrogen receptor (ER) status with lower mean K (i) -67 index (34.41 vs. 52.02%; p = 0.02), PT-SUV (max) (5.40 vs. 8.68; p = 0.036), PT-MTV (4.71 cc vs. 7.46 cc; p = 0.05), and PT-TLG (15.12 g/mL.cc vs. 37.10 g/mL.cc; p = 0.006). On multivariate analysis, only LVI status was a significant independent predictor of SLNB status (odds ratio = 6.23; 95% confidence interval: 1.15–33.6; p = 0.033). Conclusion SLNB is positive in approximately 20% of early breast cancers with PET/CT negative axilla and SLNB status appears to be independent of PT size. SLNB+ PTs were more likely to be LVI+ and ER + ve, with lower grade/K (i) -67/metabolic activity (SUV (max) /MTV/TLG) compared with SLNB–ve tumors. Logistic regression analysis revealed LVI status as the only significant independent predictor of sentinel lymph node status. Thieme Medical and Scientific Publishers Pvt. Ltd. 2022-06-28 /pmc/articles/PMC9296246/ /pubmed/35865159 http://dx.doi.org/10.1055/s-0042-1750333 Text en World Association of Radiopharmaceutical and Molecular Therapy (WARMTH). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited. |
spellingShingle | Chinnappan, Sheela Chandra, Piyush Kumar, Senthil Sridev, M.B. Jain, Deepti Chandran, Ganesan Nath, Satish Prediction of Sentinel Lymph Node Biopsy Status in Breast Cancers with PET/CT Negative Axilla |
title | Prediction of Sentinel Lymph Node Biopsy Status in Breast Cancers with PET/CT Negative Axilla |
title_full | Prediction of Sentinel Lymph Node Biopsy Status in Breast Cancers with PET/CT Negative Axilla |
title_fullStr | Prediction of Sentinel Lymph Node Biopsy Status in Breast Cancers with PET/CT Negative Axilla |
title_full_unstemmed | Prediction of Sentinel Lymph Node Biopsy Status in Breast Cancers with PET/CT Negative Axilla |
title_short | Prediction of Sentinel Lymph Node Biopsy Status in Breast Cancers with PET/CT Negative Axilla |
title_sort | prediction of sentinel lymph node biopsy status in breast cancers with pet/ct negative axilla |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9296246/ https://www.ncbi.nlm.nih.gov/pubmed/35865159 http://dx.doi.org/10.1055/s-0042-1750333 |
work_keys_str_mv | AT chinnappansheela predictionofsentinellymphnodebiopsystatusinbreastcancerswithpetctnegativeaxilla AT chandrapiyush predictionofsentinellymphnodebiopsystatusinbreastcancerswithpetctnegativeaxilla AT kumarsenthil predictionofsentinellymphnodebiopsystatusinbreastcancerswithpetctnegativeaxilla AT sridevmb predictionofsentinellymphnodebiopsystatusinbreastcancerswithpetctnegativeaxilla AT jaindeepti predictionofsentinellymphnodebiopsystatusinbreastcancerswithpetctnegativeaxilla AT chandranganesan predictionofsentinellymphnodebiopsystatusinbreastcancerswithpetctnegativeaxilla AT nathsatish predictionofsentinellymphnodebiopsystatusinbreastcancerswithpetctnegativeaxilla |